Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience RUO SARS-CoV-2 NGS Assay, Biotia COVID-Dx Software

Twist Bioscience has launched its research use-only SARS-CoV-2 next-generation sequencing assay.

The capture-based assay is for detection, characterization, and environmental monitoring of the virus from nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swabs, as well as nasopharyngeal wash/aspirates, nasal aspirates, and bronchoalveolar lavage specimens. It was validated on Illumina's NextSeq platform and includes Twist's synthetic SARS-CoV-2 RNA controls. The limit of detection is 800 viral copies/ml.

The test comes with COVID-Dx comprehensive data analysis software from Biotia, which provides an RUO report on the presence or absence of SARS-CoV-2 virus, the full sequence of the virus, genetic variants, and phylogenetic analysis.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.